National Committee for Clinical Laboratory Standards for broth macrodilution tests with antifungal agents were used: inocula standardized to 1 x 104 to 5 x 104 CFU/ml with a spectrophotometer, RPMI 1640 medium buffered with morpholinopropanesulfonic acid (pH 7.0), incubation at 35°C for 24 to 48 h, and an additive drug dilution procedure. Broth microdilution MICs were higher (two or more dilutions) than broth macrodilution MICs for all isolates tested with amphotericin B and for most isolates tested with ketoconazole, fluconazole, and cilofungin. MICs of flucytosine were the same by both techniques or lower by the broth microdilution test except in tests with C. neoformans. However, the only statistically significant differences between the two tests were observed with amphotericin B against all isolates (P = 0.01 to 0.07), ketoconazole against C. neoformans (P = 0.01 to 0.02), and cilofungin against C. albicans (P = 0.05 to 0.14). Tests performed with less dense inocula
(1 x 103 to 5 x 103) produced similar results.
MICs of antifungal drugs can be determined by using broth macro-and microdilution and agar dilution techniques. MICs quantitatively measure the in vitro activities of antifungal compounds against isolates of either yeasts or molds. Infections caused by fungi have become more frequent because of the increased use of cytotoxic and antibacterial drugs and, more recently, because of the occurrence of serious fungal infections in patients with AIDS. Although there is no need to perform antifungal susceptibility tests for every fungal isolate that causes disease, there are instances, listed below, when these tests are warranted and may be extremely useful.
Susceptibility testing with the synthetic antimetabolite flucytosine is desirable for all yeast isolates, some isolates of Aspergillus spp., and some of the dematiaceous fungi. Most other fungi, including the dimorphic fungi, are resistant to flucytosine, and hence, these tests are not needed. In vitro susceptibility tests with flucytosine are not only important for yeasts prior to treatment but also for isolates associated with therapeutic failures or relapses. Acquired resistance to flucytosine by some yeasts has been demonstrated (17) . Most fungal isolates are susceptible to the polyene amphotericin B; however, resistance to this drug by some isolates of Candida spp., Candida lusitaniae in particular, has been reported. Also, variable results may be obtained with isolates of Aspergillus spp. (MIC range, 0.05 to 8 ,ug/ml), Pseudallescheria boydii (MIC range, 1.56 to -100 ,ug/ml), Sporothrix schenckii (MIC range, 1.56 to 12.5 ,ug/ml), and the Zygomycetes (MIC range, 0.78 to 4 jig/ml) (17) . Susceptibility testing of the synthetic imidazoles and triazoles for yeasts has yet to be proven beneficial. The susceptibilities of yeasts to these drugs are variable, and selected resistance to them has been reported (16 in vitro susceptibility testing is an important aid in the initiation and monitoring of antifungal therapy (5, 17) .
The most widely used test for antifungal MIC determinations is the broth macrodilution test; it also permits determination of minimum fungicidal (lethal) concentrations. However, none of the antifungal susceptibility tests, including the broth macrodilution test, are standardized (6, 7, 11) . Results of antifungal susceptibility tests are influenced by medium composition, pH, inoculum size, and incubation time and temperature, especially with the imidazoles (2). The National Committee for Clinical Laboratory Standards (NCCLS) Subcommittee on Antifungal Susceptibility Tests is engaged in the process of standardizing antifungal susceptibility testing. This working group already has provided preliminary recommendations for broth macrodilution susceptibility testing for some yeasts (13, 14) . One of their aims is to standardize antifungal susceptibility testing in a way that only one medium is used for all antifungal drugs. At least four different media are being used for almost each drug (17) . Of the four most commonly used chemically defined synthetic media evaluated, RPMI 1640 medium buffered with morpholinopropanesulfonic acid (MOPS; pH 7.0) has demonstrated the most consistent results. The highest degree of correlation of MIC endpoints among different laboratories was seen when the test was incubated at 35°C for 24 h with flucytosine, amphotericin B, and ketoconazole (14) .
Broth microdilution antifungal tests are similar to broth macrodilution tests; however, they require smaller amounts of medium and reagents, including the antifungal drugs. Even though antifungal broth microdilution tests are not as widely used as broth macrodilution tests are, some laboratories perform them mostly with yeasts because their cost is lower and they are less cumbersome (8, 9, 15 Procedure. The following recommendations provided by the NCCLS subcommittee (14) for broth macrodilution susceptibility tests were used for both techniques.
(i) Medium. The medium used was RPMI 1640 from Sigma (St. Louis, Mo.); it was buffered with MOPS (Sigma) buffer to a final molarity of 0. 165 and adjusted to pH 7.0 by using 10 M NaOH. This medium contained L-glutamine and sodium bicarbonate, and sterility controls were performed for each batch of prepared medium before use.
(ii) Inoculum preparation and quantitation. (13) . The yeast cells were suspended in sterile 0.85% saline, and the turbidity of each suspension For the broth microdilution tests, the suspensions were diluted 1:10 only. These dilutions were made in sufficient volumes to inoculate each tube with 0.9 ml or each well with 10 ,ul. For the second inoculum size, the diluted suspensions were further diluted 1:10. This resulted in inoculum sizes of approximately 1 x 103 to 5 x 103 CFU/ml.
(iv) Drug dilutions. Both broth macro-and microdilution tests were performed by using the same additive twofold drug dilutions to reduce pipetting errors (12) . Tables 1 and 2 (6) 0.12-0.5/1-2 <0.12->64/<0.12->64 0.12-0.5/0.5-1. show examples of the dilution schema used. The broth macrodilution tests were performed with sterile, disposable tubes (12 by 75 mm; Falcon, Oxnard, Calif.). Drug dilutions were made 10 times (e.g., 640 to 1.20 ,ug/ml for flucytosine and fluconazole and 40 to 0.6 ,ug/ml for amphotericin B, ketoconazole, and cilofungin) the strength of the final drug concentrations by using medium as the diluent. The drug dilutions were dispensed in 0.1-ml volumes into each tube. These drug dilutions were made in sufficient volumes for both broth macro-and microdilution tests performed each time and were stored at -70°C for 2 to 4 weeks or overnight at 4 to 6°C before testing. When each tube was inoculated with 0.9 ml of adjusted yeast suspension, the actual 1 x range of drug concentrations was achieved. Final drug concentrations ranged from 64 to 0.12 ,ug/ml for flucytosine, fluconazole, and cilofungin and 4 to 0.06 ,ug/ml for amphotericin B and ketoconazole for both tests. The broth microdilution tests were performed with sterile, disposable microtitration multiwell plates (Flow Laboratories, McLean, Va.). For the broth microdilution tests, the lOx strength drug concentrations were diluted 1:10 with medium and dispensed into the wells (rows 1 to 10 or 1 to 7) of the sterile microtiter plates in 100-,u volumes with a multichannel pipette. Row 1 contained the highest drug concentration, and row 7 or 10 contained the lowest drug concentration. The microtiter plates were stored inside plastic bags at -70°C or overnight at 4 to 6°C. The wells were inoculated on the day of the test with 10 ,u1 of adjusted cell suspension. In this way, each tube and/or well contained approximately the same inoculum size per milliliter. The control organisms were handled in the same way and were included in each set of both tests. The growth control tubes contained 1 ml of each inoculum size, and the growth control wells contained 100 ,ul of drug-free medium and 10 ,ul of inoculum. Broth microdilution susceptibility tests of amphotericin B also were performed against 16 other yeasts, representing all the species listed in Table 3 (14) . The broth microdilution MIC endpoints were determined with a reading mirror (Cooke Engineering Co., Alexandria, Va.). Growth in each drug concentration tube or well was compared with growth in the control (drug-free) tube or well and given a score as follows: 4+, no reduction of turbidity or growth; 3+, slight reduction in turbidity; 2+, about 50% reduction in turbidity; 1+, slightly hazy turbidity; and 0, optically clear. MICs of amphotericin B, flucytosine, and cilofungin were defined as the lowest drug concentration in which there was absence of growth (scored 0). For fluconazole and ketoconazole, the endpoint was the tube and/or well that showed 1+ or less growth or turbidity.
RESULTS
All yeast isolates tested, with the exception of C. neoformans, produced clearly detectable growth at 24 h in RPMI 1640 medium, and MIC endpoints were determined at that time. Isolates of C. neoformans showed less growth at 24 h in the MIC tubes, but they grew well in the microtiter wells. Therefore, microdilution MICs could be determined more easily than macrodilution MICs could at 24 h for C. neoformans isolates with the higher inoculum. When the lower inoculum was used, MIC endpoints could not be determined by either test at 24 h. The inoculum quantitations of the yeast suspensions ranged from 0.9 x 106 to 7 x 106 CFU/ml for the 38 yeasts tested and for each of the 3 control organisms included in each set (seven) of tests performed.
The MICs were determined in seven separate sets of experiments. The MIC ranges for both broth macro-and microdilution tests of the five drugs tested against the 38 pathogenic yeasts and the control organisms, using the denser inoculum, are summarized in Table 3 However, cilofungin, ketoconazole, and flucytosine MICs increased, sometimes by two or more dilutions at 48 h in both tests. In general, lower inoculum size suspensions produced lower MIC endpoints.
Differences between the two tests of two dilutions or more and their frequencies are summarized in Table 4 . In a few instances, mostly with flucytosine and fluconazole, the differences were seen with the 48-h MIC endpoints only. The differences between both techniques with both inocula were similar. Amphotericin B broth microdilution MICs were consistently higher than broth macrodilution MICs against all the isolates of the five species tested at both 24 and 48 h. No differences were observed with flucytosine against most of the species, with the exception of some isolates of C. tropicalis and C. neoformans, and in contrast, some broth microdilution MICs were lower than broth macrodilution MICs. Similar results also were obtained with fluconazole against several isolates of C. albicans, C. parapsilosis, and T. glabrata. Broth microdilution MICs also were higher than broth macrodilution MICs with ketoconazole and cilofungin against some isolates of most species, with the exceptions of C. lusitaniae and C. parapsilosis.
The Wilcoxon signed rank test, when it was assumed that the median of the difference was zero or no difference between broth micro-and macrodilution MIC results, also was applied. A summary of the P values is presented in Table 5 for both 24-and 48-h readings with the denser inocula. A P value of c0.05 was considered statistically significant. Therefore, the only significant differences between the two tests at 24 h were observed with amphotericin B against all the isolates (using Flow microtiter plates), ketoconazole against C. neoformans, and cilofungin against C. albicans.
DISCUSSION
In this study, statistical analysis demonstrated a good correlation between broth micro-and macrodilution MIC endpoints when they were obtained according to the NCCLS subcommittee recommendations for the broth macrodilution antifungal susceptibility testing of yeasts. In 1982, NCCLS established the Subcommittee on Antifungal Susceptibility Tests. Since then, two collaborative studies have been reported regarding the endeavors of this group to standardize antifungal susceptibility testing (13, 14) . The first collaborative study (13) focused on one of the test variables, the preparation of inocula. Four methods of inoculum prepara- Candida lusitaniae (6) b ND, not done; there were no differences between results of the two tests.
tion were compared: the spectrophotometric method, the Wickerham card method, the hemacytometer method, and the then new, commercially available Prompt inoculation system (3M). The spectrophotometric method provided the least variable results among the different laboratories, and it was the method recommended by the NCCLS subcommittee for use in future standardization of antifungal susceptibility testing of yeasts. Therefore, this was the method used for our comparison study of antifungal broth macro-and microdilution susceptibility tests. Our results confirmed that this method provides reliable yeast suspensions, as demonstrated by the consistent range of CFU per milliliter achieved (0.9 x 10' to 7 x 106) in this study with the 38
yeasts and the control isolates tested.
Other assays of quantitation of fungi and standardization of yeast inocula have been reported previously (1, 3) . However, the spectrophotometric method evaluated by Pfaller et al. (13) provided suitable yeast suspensions in our study. In another study of Pfaller et al. (14) , it also gave consistent intra-and interlaboratory MIC endpoints; moreover, this method can be performed quickly and easily and is familiar to most laboratory personnel. One of the shortcomings associated with the spectrophotometric method is that inoculum size is influenced by cell size. This may be bypassed by adjusting the fungal cell suspensions to different percent transmissions (4).
The second NCCLS antifungal collaborative study, using a broth macrodilution method (14) , evaluated the effect of medium, incubation time (24 versus 48 h), and incubation temperature (30 versus 35°C) on intra-and interlaboratory variations of MIC endpoints of amphotericin B, flucytosine, and ketoconazole. Four different buffered (MOPS), chemically defined media were evaluated: yeast nitrogen base medium, RPMI 1640 medium, synthetic amino acid medium, and high-resolution antifungal assay medium. The highest agreement among laboratories, including the rank order of susceptibility, was obtained with RPMI 1640 medium at 35°C and after a 24-h incubation time with all three antifungal compounds. Because of this, we chose the buffered RPMI 1640 medium for our comparison study of the two methods.
It also is essential that the medium selected for susceptibility testing supports suitable growth of all the isolates being tested. In both our study and the previous NCCLS group study (14) , RPMI 1640 medium supported growth of all species tested. However, in our study, isolates of C. neoformans grew more slowly than the other yeasts did at 24 h. This was more prevalent with the lower inoculum. Therefore, MIC endpoints could be obtained at 24 h by the broth microdilution but not always by the broth macrodilution test with isolates of C. neoformans, because the latter isolates grew better in the microdilution wells than they did in the tubes. This could be the result of either the magnified detection of growth in the wells provided by the reading mirror or the absolute number of yeast cells within the wells. The second MIC reading for these isolates was then done at 72 h.
Previous reports of collaborative MIC studies have demonstrated significant divergent susceptibilities of yeasts, among the different laboratories, to all drugs tested, including amphotericin B (7, 11) . Our broth macrodilution MIC data of the six yeasts previously used in the second NCCLS collaborative study (14) correlated with the MIC endpoints obtained in that study. Since the discrepancies between the broth macro-and microdilution tests were not statistically significant, with the exception of amphotericin B MICs (Table 5) , the broth microdilution test provided consistent results in this study. This also was demonstrated by the reproducibility of the susceptibilities to the five drugs on the part of the three control organisms in each of the seven broth macro-and microdilution sets of experiments performed (Table 3) . A broth microdilution antifungal test done with RPMI 1640 tissue culture medium has been reported (15) to provide reproducible MIC results. Radetsky et al. (15) and other investigators (8, 9) also have found that the broth microdilution technique is more efficient, economical, and easier to perform than is the agar dilution test (9) , one of the currently used methods of susceptibility testing. In our study, all broth microdilution MICs (higher inoculum) could be determined at 24 h, in contrast to some broth macrodilution MICs for C. neoformans isolates, which needed 48 h of incubation. We also found the broth microdilution test to be a faster and easier test to perform than the broth macrodilution test was.
The denser inoculum suspensions produced MIC endpoints higher than those of the lower inoculum suspensions, as reported previously (10) . In our comparison study of broth macro-and microdilution tests, similar discrepancies were observed between results of both tests with both inocula. It has been suggested that broth macrodilution MICs correlated better with the in vivo efficacy of the new triazole SCH 39304 when the test is performed with suspensions lower than 1 x 104 to 5 x 104 CFU/ml (10) . A well inoculum of i03 CFU also has been reported to provide MIC endpoints which correlated with both patient and animal outcome data (15) . The current collaborative NCCLS study is assessing two inoculum densities similar to the ones used in this study, and a more definitive answer should be provided by that group.
The determination of MIC endpoints is a difficult step in antifungal susceptibility testing, especially with the imidazoles and triazoles. The partial inhibition (slight turbidity) observed with these compounds accounts for the lack of well-defined MIC endpoints. This slight turbidity was scored in the NCCLS study (14) and in our study as 
